Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Summit Therapeutics ( (SMMT) ) just unveiled an update.
On October 21, 2025, Summit Therapeutics Inc. announced it entered into securities purchase agreements with leading biotech investors, raising approximately $500 million through a private placement of common stock. The funds will be used to advance the clinical development of ivonescimab, a novel investigational bispecific antibody, and for general corporate purposes. The private placement included significant participation from Summit’s executives and Akeso, Inc., highlighting strong insider confidence. The closing of the transaction is expected by October 28, 2025, and Summit plans to file a registration statement with the SEC for the resale of the shares.
The most recent analyst rating on (SMMT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.
Spark’s Take on SMMT Stock
According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.
Summit Therapeutics’ stock score reflects significant financial challenges, including lack of revenue and ongoing losses, balanced by a strong equity position. Technical indicators show positive momentum, supporting short-term interest. Valuation remains weak due to negative earnings and no dividend. Positive clinical developments from the earnings call bolster the score, highlighting potential for future growth.
To see Spark’s full report on SMMT stock, click here.
More about Summit Therapeutics
Summit Therapeutics Inc. is a biopharmaceutical oncology company that focuses on discovering, developing, and commercializing therapies aimed at improving quality of life and addressing serious unmet medical needs. Founded in 2003, Summit is listed on the Nasdaq Global Market under the symbol ‘SMMT’ and is headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK.
Average Trading Volume: 3,959,025
Technical Sentiment Signal: Buy
Current Market Cap: $14.91B
For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.